Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. by Verdoux, Hélène et al.
Serious psychiatric outcome of subjects prenatally
exposed to diethylstilboestrol in the E3N cohort study.
He´le`ne Verdoux, Jacques Ropers, Dominique Costagliola, Franc¸oise
Clavel-Chapelon, Xavier Paoletti
To cite this version:
He´le`ne Verdoux, Jacques Ropers, Dominique Costagliola, Franc¸oise Clavel-Chapelon, Xavier
Paoletti. Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in
the E3N cohort study.. Psychological Medicine, Cambridge University Press (CUP), 2007, 37
(9), pp.1315-1322. <10.1017/S0033291707000438>. <inserm-00145139>
HAL Id: inserm-00145139
http://www.hal.inserm.fr/inserm-00145139
Submitted on 9 May 2007
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Serious psychiatric outcome of subjects prenatally exposed to 
diethylstilboestrol in the E3N cohort study 
 
Hélène Verdoux
1
, Jacques Ropers
2
, Dominique Costagliola
3
, Françoise Clavel-Chapelon
4
 and 
Xavier Paoletti
5*
 
1
 INSERM U657; Université Segalen-Bordeaux 2, Bordeaux, France; 
2
 Agence Française de Sécurité Sanitaire des Produits 
de Santé, St Denis, France; 
3
 INSERM U720, Paris, France; 
4
 INSERM, Equipe E3N, Villejuif, France; 
5
 INSERM U738, 
Paris, France 
 
 
ABSTRACT 
Background. Prenatal exposure to diethylstilboestrol (DES) may induce neurodevelopmental disturbances 
potentially mediating an increased risk of psychiatric disorders in exposed subjects. Most findings of an 
increased prevalence of psychiatric disorders in men and women prenatally exposed to DES are not easy to 
interpret because of selection biases. 
Method. Information on hormonal treatment during pregnancy and on offspring’s medical outcome was 
collected from women participating in the Etude Epidemiologique de Femmes de la Mutuelle Générale de 
l’Education Nationale (E3N) prospective cohort who completed consecutive postal questionnaires on a range of 
medical events since 1990. Information on hormonal treatment during pregnancy was collected in 1992 and on 
offspring’s medical outcome in 2004. The psychiatric outcome of subjects prenatally exposed to DES was 
compared to that of their unexposed siblings. 
Results. A total of 1352 mothers with DES treatment for at least one pregnancy provided information on 1680 
exposed children and 1447 unexposed siblings. After adjustment for duration of follow-up, educational level, 
history of obstetric complication, prenatal exposure to progestagen drugs or other hormones and parental history 
of psychiatric hospitalization, no association was found between prenatal exposure to DES and occurrence of 
strictly defined serious psychiatric outcome (suicide or psychiatric hospitalization) [adjusted odds ratio (OR) 0.8, 
95% confidence interval (CI) 0.5–1.2], or of broadly defined serious psychiatric outcome (same events plus 
psychiatric or psychological consultation) (adjusted OR 1.0, 95% CI 0.8–1.2). 
Conclusions. These findings suggest that the impact of prenatal DES exposure on foetal brain development, if 
any, is unlikely to increase the risk of serious psychiatric disorders. 
 
 
INTRODUCTION 
There is accumulating evidence that subjects with perinatal exposure to environmental events disturbing 
neurodevelopment are at increased risk of psychiatric disorders (Murray & Lewis, 1987; Cannon et al. 2003; 
Verdoux, 2004). Few studies have investigated the impact of prenatal exposure to synthetic hormones on 
psychiatric outcome. However, intra-uterine levels of oestrogens affect foetal brain development, particularly 
cerebral lateralization (Geschwind & Galaburda, 1985). Synthetic oestrogens (or xeno-oestrogens) have a non-
steroidal structure and do not bind to peripheral alphafoetoprotein, a mechanism preventing entry into the foetal 
central nervous system; unlike endogenous oestrogens, they do not convert to oestrone, a metabolite of low 
oestrogenic activity (Schachter, 1994). Hence, high concentrations of active xeno-oestrogens reach the foetal 
brain with potential deleterious consequences on brain development (Slikker et al. 1982). Animal studies have 
shown that rodents prenatally exposed to xeno-oestrogens such as diethylstilboestrol (DES) or ethynyloestradiol 
present with a range of behavioural abnormalities (Porrini et al. 2005). Human studies suggest that DES may 
impact on the neurodevelopmental lateralization process. An excess of left-handedness in women with prenatal 
exposure to DES has been reported by several studies (Schachter, 1994; Scheirs & Vingerhoets, 1995; Smith & 
Hines, 2000), although this finding was not supported by others (Titus-Ernstoff et al. 2003); yet other studies 
found an excess of left-handedness in men with prenatal exposure to DES (Reinisch & Sanders, 1992; Titus- 
Ernstoff et al. 2003). 
                                                 
* Address for correspondence: Xavier Paoletti, Institut National du Cancer, Department of Clinical Research and Biostatistics, 52 avenue 
Morizet, 92513 Boulogne cedex, France. (Email: xpaoletti@institutcancer.fr) 
Considering that abnormal lateralization may be implicated in the pathophysiology of psychiatric 
disorders (Crow et al. 1996; Orr et al. 1999), DES-induced neurodevelopmental disturbances may potentially 
mediate an increased risk of psychiatric disorders in exposed subjects. Contradictory findings have been reported 
by previous studies exploring this issue (Vessey et al. 1983; Meyer-Bahlburg et al. 1985; Ehrhardt et al. 1987; 
Fried-Cassorla et al. 1987; Gustavson et al. 1991; Pillard et al. 1993; Titus-Ernstoff et al. 2003). 
Although DES is no longer prescribed, its impact on psychiatric outcome should be clarified, 
considering the numerous subjects prenatally exposed to DES up to the 1970s (around 8 000 in UK, more than 
150 000 in the Netherlands and in France and nearly 5 million in the USA; Palmlund et al. 1993). Furthermore, 
because of the persisting risk of prenatal exposure to environmental xeno-oestrogens (Newbold, 2004), DES 
studies are of value as a model of exposure to these substances. We investigated, in the French prospective 
cohort Etude Epidemiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N), whether 
psychiatric outcome differed between subjects prenatally exposed to DES and their unexposed siblings. 
 
METHOD 
Sample 
Participants were mothers of a subgroup of the E3N cohort who completed questionnaires about their 
children for the present study. The E3N was initiated in 1990 to study risk factors for cancer in women (Clavel-
Chapelon, 2002; Romieu et al. 2003; Fournier et al. 2005; Tehard et al. 2005). At baseline, the cohort included 
97 995 women fulfilling the following inclusion criteria: (i) born between 1925 and 1950; (ii) covered by the 
national health insurance plan for French teachers (MGEN) ; and (iii) giving written informed consent to 
participate in the investigation. Information on a range of medical events is collected using postal questionnaires 
approximately every 24 months since 1990. 
The process for subject selection included in the present study is presented in Fig. 1. Information on hormonal 
treatments during pregnancy was collected in the 1992 questionnaire sent to the whole cohort and completed by 
87.9% of the women included at baseline. From this initial pool, we identified all women still alive who reported 
giving birth to at least one child exposed to DES in utero. They were sent a postal questionnaire in 2004. The 
cover letter mentioned only that the aim of the survey was to explore the impact of perinatal events on children’s 
health. The hypothesis addressed in the present study and the fact that women had been selected on the basis of 
their prior answer to the DES item were not specified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
FIG. 1. Selection of the subjects prenatally exposed to DES and their unexposed siblings. 
86163 women participating in the 
1992 postal survey 
 
1515 women having reported DES 
prescription for at least one pregnancy in 
the 1992 survey, alive in 2004 
 
3272 children with questionnaires 
completed by their mothers 
3127 children (of 1352 mothers) alive at 
12 years of age 
 
1680 subjects prenatally 
exposed to DES 
1447 unexposed siblings 
1374 women participating in the 2004 
postal survey (response rate: 91%) 
 
Assessment of prenatal exposure to DES and other hormones 
According to the information reported by the mother in the 1992 questionnaire, three variables were 
derived for each child : prenatal exposure to (i) DES; (ii) progestagen drugs ; (iii) other hormones. To facilitate 
accurate recall, a leaflet with colour photographs of the hormonal treatments marketed in France accompanied 
the questionnaire. The presence or absence of hormonal treatment was recorded, without further information on 
motive for prescription, dose, duration or stage of pregnancy. 
 
Assessment of child’s outcome 
In 2004, the women were asked to complete a questionnaire for each biological child born alive (up to 
five). Information collected included (i) history of obstetric complications using questions (see Table 1) derived 
from the Lewis and Murray scale (this scale has been widely used to explore the association between obstetric 
complications and psychiatric outcome in studies based upon maternal recall ; Lewis & Murray, 1987; Verdoux 
et al. 1997); (ii) demographic characteristics, including cause of death; (iii) reproductive status : parity, history 
of miscarriage and of difficulties to conceive; if the answer was positive to the latter item, the mother was asked 
to specify if, to her knowledge, these difficulties were attributable to her child, to her partner, or of unknown 
origin ; nulliparity and difficulties to conceive attributable to her child were categorized as ‘ infertility strictly 
defined’, nulliparity and difficulties to conceive not attributable to the child or of unknown origin were 
categorized as ‘ infertility broadly defined’ ; (iv) lifetime medical history of hospitalization or consultation with 
specialists, and age at first hospitalization: women were proposed a list of 15 possible reasons for hospitalization 
(including psychiatric hospitalization) and a similar list of speciality names (including consultation with a 
psychiatrist or a psychologist). We defined two categories of psychiatric outcome: (i) lifetime history of strictly 
defined serious psychiatric outcome if the mother reported that her son or daughter committed suicide or had 
been hospitalized in psychiatry ; and (ii) lifetime history of broadly defined serious psychiatric outcome 
including the previous events or a history of consultation with a psychiatrist or a psychologist. 
 
Table 1. Characteristics of subjects prenatally exposed to DES and their unexposed siblings 
 Subjects with prenatal DES 
exposure n (%) or mean (S.D.) 
(n=1680) 
Siblings without prenatal DES 
exposure n (%) or mean (S.D.) 
(n=1447) 
Demographic characteristics 
   Duration of follow-up (years)
a
 
   Male gender  
   Educational level >14 years  
 
36.8 (7 . 4) 
751 (44.7)) 
1189 (71.8) 
 
36.5 (5.5) 
781 (54.0 
952 (67.2) 
Obstetric history 
   Definite obstetric complication
b 
   Prenatal exposure to progestagen  
   Prenatal exposure to other hormones  
 
1331 (79.2) 
632 (37.6) 
87 (5.2) 
 
561 (38.8) 
281 (19.4) 
75 (5.2) 
History of maternal or paternal 
psychiatric hospitalization 
74 (4.4) 61 (4.2) 
DES, Diethylstilboestrol ; S.D., standard deviation. 
a
 Age of the children still alive in 2004, or age at the time of death. 
b
 At least one definite obstetric complication according to the Lewis and Murray scale (Lewis & Murray, 1987): threatened 
abortion; antepartum bleeding; severe hypertension requiring hospitalization ; caesarean for emergency delivery; breech 
presentation; premature birth >3 weeks; postmature birth >2 weeks; birthweight <2000 g; incubator used >4 weeks. 
 
 
In addition, history of hospitalization in the first- and second-degree biological relatives of each child 
was collected. The above list of medical motives was used. In the present study only information on psychiatric 
hospitalization was used as a proxy measure of family history of psychiatric disorder. We applied a narrow 
definition of positive family history of psychiatric disorder, restricted to history of psychiatric hospitalization in 
the mother or in the biological father. 
 
 
Statistical methods 
We investigated the relationship between exposure to DES and psychiatric outcome overall and after 
stratification by gender. We also explored the relationship between DES exposure and reproductive status in 
daughters (history of miscarriage, nulliparity and infertility) to serve as a tool to validate maternal information, 
as the increased frequency of such events in DES-daughter has been largely documented elsewhere (Kaufman et 
al. 2000). Finally, we performed a sensitivity analysis to check that removing non-significant variables or 
modifying correlation structure did not modify the other estimates (results available on request). 
Characteristics of the exposed and unexposed children were compared statistically using the χ2 test. 
Multivariate analyses were performed to assess associations between each outcome of interest and exposure to 
DES, progestagen drugs or other hormones. The models were adjusted for follow-up duration (calculated as the 
age for children still alive in 2004 or the age at death), sex, educational level (dichotomized as above or below 
14 years), history of obstetric complications and family history of psychiatric hospitalization. All variables 
except follow-up were treated as binary. Because of the large sample size, model selection was unnecessary, 
thereby limiting the risk of bias. Separate models were generated for strictly and broadly defined serious 
psychiatric outcomes. All variables included in the models were specified in the analysis plan blind to the data. 
To take into account intra-family correlation, a hierarchical two-level logistic model was used (Watier et 
al. 1997). The child’s level was embedded in the family level, making it possible to estimate and to take into 
account correlation between siblings. An exchangeable correlation structure assuming common correlation 
among all siblings was used. The generalized estimating equations (GEE) approach provided estimates and 95% 
confidence intervals (CIs). Adjusted odds ratios (aORs) are reported. All tests were two-tailed. Statistical 
analyses were performed with SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
Characteristics of the sample 
Numbers of respondents and children included in the study are given in Fig. 1. Few data were missing 
for most items of the questionnaire, limiting a posteriori loss of power; obstetrical complications variables had 
the highest frequency of missing data (around 10%) but sensitivity analyses with different imputation strategies 
led to the same results. The mean age of the mothers was 65 years (S.D.=5.8, range 54–80). Only children alive 
at 12 years of age and without history of psychiatric hospitalization before age 12 were considered, in order to 
exclude subjects with severe infancy or childhood psychiatric disorders such as mental retardation or pervasive 
development disorders, because inclusion of these subjects may have contributed to increase the heterogeneity of 
the spectrum of disorders considered in the psychiatric outcome. The mean duration of follow-up was 36 years 
(S.D.=6.4, range 12–57) and was 30 years and over for most (90%) children. 
The characteristics of the subjects with prenatal DES exposure and of their unexposed siblings are given 
in Table 1. Irrespective of exposure status, most subjects had a high educational level. Nearly four out of five 
children prenatally exposed to DES had a history of definite obstetric complications, the most frequent being 
threatened abortion (69.7% of DES-exposed subjects ; 21.4% of unexposed siblings) and antepartum bleeding 
(41.8% of DES-exposed subjects ; 13.5% of unexposed siblings). Statistical tests indicate that both groups are 
not significantly different for all characteristics except for sex, progestagen exposure and obstetrical 
complications. These two latter differences were expected because DES was given to pregnant women with a 
history of prior complicated pregnancy and was often co-prescribed with progestagens. 
 
Prenatal hormonal exposure and psychiatric outcome 
In the overall sample, subjects (n=16) who committed suicide had a median age of 27 years [interquartile 
range (IQR) 23–31, range 18–43]. The median age at first psychiatric hospitalization was 24 years (IQR 20–32, 
range 13–47). The comparison of psychiatric outcome according to prenatal DES exposure status is given in 
Table 2.  
Subjects prenatally exposed to DES were not at increased risk of presenting with a lifetime history of 
suicide or psychiatric hospitalization compared to their unexposed siblings. No association was found between 
prenatal DES exposure and serious psychiatric outcome broadly defined. Similar findings were obtained in 
analyses stratified by gender: the occurrence of strictly defined serious psychiatric outcome did not differ 
between women prenatally exposed to DES and their unexposed sisters (aOR 0.8, 95% CI 0.5–1.4, p = 0.49) or 
between men exposed to DES and their unexposed brothers (aOR 0.80, 95% CI 0.37–1.67, p = 0.56). 
Table 2. Psychiatric outcome of subjects prenatally exposed to DES and their unexposed siblings 
 Subjects with prenatal 
DES exposure n (%) 
Siblings without prenatal 
DES exposure n (%) 
Adjusted OR  
(95% CI)
a
 
Suicide  
Psychiatric hospitalization  
Strictly defined serious psychiatric outcome
b
 
Consultation with a psychiatrist  
Consultation with a psychologist  
Broadly defined serious psychiatric outcome
c
  
9 (0.5) 
60 (3.6) 
60 (3.6) 
194 (11.6) 
199 (11.9) 
330 (19.6) 
7 (0.5) 
55 (3.8) 
58 (4) 
147 (10.2) 
162 (11.2) 
267 (18.5) 
 
 
0.8 (0.5–1.2), p = 0.22 
 
 
1.0 (0.8–1.2), p = 0.86 
DES, Diethylstilboestrol ; OR, odds ratio ; CI, confidence interval. 
a Adjusted for duration of follow-up, educational level, history of at least one definite obstetric complication according to 
the Lewis and Murray scale (Lewis & Murray, 1987) (see Table 1), prenatal exposure to progestagen drugs or other 
hormones, paternal or maternal history of psychiatric hospitalization. 
b Suicide or psychiatric hospitalization. 
c Suicide, psychiatric hospitalization or consultation with a psychiatrist or a psychologist. 
 
 
In the model adjusted for DES exposure and other potential confounding factors (see Table 1), no 
association was found between (i) prenatal exposure to progestagen drugs and serious psychiatric outcome 
(strictly defined: aOR 1.2, 95% CI 0.8–1.9, p=0.33; broadly defined: aOR 1, 95% CI 0.8–1.2, p = 0.99); (ii) 
prenatal exposure to other hormones and serious psychiatric outcome (strictly defined: aOR 0.8, 95% CI 0.3–1.8, 
p = 0.57; broadly defined: aOR 1.2, 95% CI 0.8–1.7, p = 0.41). 
 
Prenatal exposure to hormones and daughters’ obstetrical outcome during adulthood 
The frequency of nulliparity did not differ between daughters prenatally exposed to DES compared to 
their unexposed sisters [n = 229 (27.1%) v. n = 156 (26.6%), aOR 1.1, 95% CI 0.8–1.4, p = 0.52]. A history of 
miscarriage was more frequently reported in daughters prenatally exposed to DES compared to their unexposed 
sisters [n = 189 (22.3%) v. n = 97 (16.5%), aOR 1.4, 95% CI 1.1–1.9, p = 0.01]. Significant associations were 
found between prenatal DES exposure and infertility strictly defined [exposed daughters n = 79 (9.4%) v. 
unexposed sisters n = 16 (1.7%), aOR 3.4, 95% CI  2.0–6.0, p = 0.0001] or infertility broadly defined [exposed 
daughters n = 110 (13.1%) v. unexposed sisters n = 42 (7.2%), aOR 2.1, 95% CI 1.4–3.1, p = 0.0001]. No 
association was found between prenatal exposure to progestagen drugs and nulliparity (aOR 1.1, 95% CI 0.8–
1.4, p = 0.55), history of miscarriage (aOR 0.9, 95% CI 0.7–1.2, p = 0.52), and infertility strictly (aOR 1.4, 95% 
CI 0.9–2.2, p = 0.18) or broadly (aOR 1.2, 95% CI 0.8–1.7, p = 0.36) defined. No association was found between 
prenatal exposure to other hormones and nulliparity (aOR 1.0, 95% CI 0.6–1.6, p = 0.90), history of miscarriage 
(aOR 1.1, 95% CI 0.6–2.1, p = 0.77), and infertility strictly (aOR 0.6, 95% CI 0.2–1.8, p = 0.31) or broadly 
(aOR 1.1, 95% CI 0.5–2.3, p = 0.84) defined. 
 
DISCUSSION 
Serious psychiatric outcome did not differ between subjects prenatally exposed to DES and their 
unexposed siblings. A history of miscarriage and of infertility was more frequent in women prenatally exposed 
to DES compared to their unexposed sisters. 
 
Strengths and weaknesses 
First, memory bias may limit the validity of maternal recall on pregnancy events, particularly 
medications prescribed during pregnancy. As we have little reason to suspect that this bias differed 
systematically according to offspring’s psychiatric outcome, such a misclassification may have contributed to 
reduce the strength of the association. However, information on DES exposure was collected 14 years before the 
present survey, the mothers were not informed about the aim of this study, and their report of DES impact on 
their daughters’ obstetric outcome at adulthood was in accordance with the documented genital consequences of 
DES (Kaufman et al. 2000). Second, mothers may not be fully informed about the psychiatric outcome of their 
children, such as psychiatric consultation, but it is unlikely that they were not aware of events such as suicide or 
psychiatric hospitalization, or that they systematically under-reported psychiatric events for DES-exposed 
subjects compared to their unexposed siblings. However, we cannot exclude a nonsystematic misclassification of 
broadly defined serious psychiatric outcome that may have attenuated the strengths of the associations. Third, 
mothers and children were not representative of the general population with regard to educational level, but is it 
unlikely that educational level modifies the neurodevelopmental impact of prenatal DES exposure. Fourth, no 
information was available on duration, dose and time of DES exposure during pregnancy, which may have 
attenuated the strength of the association if these characteristics modify the impact of DES exposure on 
psychiatric outcome. However, such information was no more available in prior studies reporting an association 
between DES exposure and increased risk of psychiatric disorders.  
The major strengths of the study are the high response rate, the large sample size limiting the risk of type 
II error, and the fact that most offspring had passed beyond the age of peak incidence of major psychiatric 
disorders. In particular, for a prevalence of psychiatric disorders around 10% and an intra-family correlation 
between 0% and 50%, the study had a 80% power to detect a non-adjusted OR between 1.3 and 1.1 respectively. 
 
Interpretation of findings 
Studies have reported that the prevalence of psychiatric disorders, particularly depression or eating 
disorders, is increased in women or men prenatally exposed to DES (Vessey et al. 1983; Meyer-Bahlburg et al. 
1985; Gustavson et al. 1991; Pillard et al. 1993). Most of these studies were hampered by selection biases, the 
sampling procedure selecting, for example, women recruited in DES specialized centres or members of users’ 
associations (Verdoux, 2002). The only exception was the study by Vessey (1983) using data from a randomized 
controlled trial performed in the 1950s comparing DES to placebo in 1000 women. Information on the medical 
outcome of their 660 children was provided in 1977–1982 by their general practitioners (GPs) blind to the 
exposure status. Subjects prenatally exposed to DES were twice as likely to present with psychiatric disorders, 
mostly anxiety and depression, compared to their unexposed siblings. Other studies did not report such an 
association (Ehrhardt et al. 1987; Fried-Cassorla et al. 1987; Titus-Ernstoff et al. 2003). The discrepancy 
between our findings and those of previous studies showing an excess of psychiatric disorders in subjects 
prenatally exposed to DES may be explained by the selection biases present in most prior studies. As psychiatric 
outcome was restricted in the present study to suicide or treatment by mental health professionals, we did not 
consider most common mental disorders treated at a primary care level, which may explain the difference 
between our findings and those reported in the study by Vessey et al. (1983). 
Compared to prior studies carried out in selected populations or those that did not differentiate 
psychiatric outcome according to severity level or need for care, the major contribution of the present study is to 
provide strong evidence that prenatal exposure to DES is not associated with an increased risk of major 
psychiatric disorder requiring hospitalization or at least consultation with a mental health specialist. Our findings 
suggest that prenatal DES exposure is unlikely to have a major impact on the development of foetal brain 
structures implicated in the pathophysiology of serious psychiatric disorders. Nevertheless, this reassuring 
finding should not obscure the fact that DES-exposed subjects, particularly DES daughters, too often have to 
cope daily with the psychological distress induced by cancer or the consequences of genital malformations 
(infertility, foetal loss), and have to be provided with adequate psychological support. 
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